drugset / Trial / NCT05524155
Sintilimab Combined With Regorafenib and HAIC in Patients With Colorectal Liver Metastasis
NaSingle-groupOpen-labelTreatment
Summary
To evaluate the safety and efficacy of sintilimab combined with regorafenib and HAIC in patients with colorectal liver metastasis who failed second-line therapy
Timeline
- Start
- 2022-09
- Primary completion
- 2024-03
- Completion
- 2024-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Leucovorin | Small molecule | — | Other |
| Subject | Oxaliplatin | Small molecule | — | Other |
| Subject | Regorafenib | Small molecule | 80 mg | Oral |
| Subject | Sintilimab | Monoclonal antibody | 200 mg | Intravenous |
| Subject | fluorouracil | Small molecule | — | Other |